30 Participants NeededMy employer runs this trial

2141-V11 for Esophageal Cancer

Recruiting at 6 trial locations
SC
SE
Overseen BySeung Eun Lee, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

Who Is on the Research Team?

SC

Samuel Cytryn, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with advanced esophageal, stomach, or gastroesophageal junction adenocarcinoma. Participants should have these cancers and be able to receive immunotherapy and chemotherapy. People with other serious health issues or who can't safely get the study drugs may not qualify.

Inclusion Criteria

My cancer is advanced and cannot be removed by surgery or has spread to other areas.
My original tumor in the esophagus or stomach is still present and visible on endoscopy.
My blood and organ tests show normal or acceptable levels for treatment.
See 8 more

Exclusion Criteria

I have had severe side effects from anti-PD-1 therapy.
Unwilling to give written informed consent, unwilling to participate, or unable to comply with protocol for study duration
I have had radiation therapy to my esophagus, stomach, or gastroesophageal junction tumor.
See 11 more

What Are the Treatments Tested in This Trial?

Interventions

  • 2141-V11
  • Fluoropyrimidine
  • Nivolumab

Trial Overview

The study tests if adding a new drug called 2141-V11 (given directly into tumors) to standard treatment—nivolumab (an immunotherapy) with or without fluoropyrimidine chemo—is safe for people with these cancers.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Phase IbExperimental Treatment3 Interventions
Group II: Phase IIExperimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Rockefeller University

Collaborator

Trials
162
Recruited
16,700+